Physician profile
Sylvia E Reyes
NPI 1144208539
$15,007.65
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,511 · 2020: $2,863 · 2021: $3,967 · 2022: $1,978 · 2023: $17.58 · 2024: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,508.20 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $3,189.10 | 2019-2022 | |
| Alkermes, INC. | $1,643.09 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,572.43 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,507.77 | 2019-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $873.08 | 2019-2022 | |
| Allergan, INC. | $446.02 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $434.69 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $403.69 | 2021-2022 | |
| Lundbeck LLC | $338.32 | 2019-2021 | |
| Abbvie INC. | $280.72 | 2021-2022 | |
| Indivior INC. | $217.44 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $167.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.54 | 2019-2021 | |
| Shire North American Group INC | $126.63 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $123.06 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.58 | 2023 | Quviviq |
| Corium, LLC | $15.86 | 2022 | |
| Noven Therapeutics, LLC | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.